English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 12 June 2024, 11:00 JST
Share:
    

Source: Olympus
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India

TOKYO, June 12, 2024 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech Company committed to making people’s lives healthier, safer and more fulfilling, today announced its strategic initiative to establish an R&D Offshore Development Center (ODC) in Hyderabad, India. This decision comes as a result of a strategic agreement with global technology company HCLTech, aimed at diversifying Olympus' innovation generation activities.

Endoscopy Engineering support services in India
Endoscopy Engineering support services in India

Establishing this R&D ODC in Hyderabad is part of Olympus' commitment to leverage global R&D talents and resources driving advancements in medical technology. Hyderabad is a major metropolitan area and is known as India’s MedTech hub, providing the talent needed for research and development activities necessary for Olympus' expansion efforts.

Concurrent with the creation of the ODC, Olympus will also prepare for the establishment of Olympus’ in-house R&D center in the coming years. This center would be in addition to the company’s current R&D centers in Japan, the United States, and Europe.

The company plans to further establish its presence in the country by collaborating with AIG Hospitals, Hyderabad for joint research projects. By partnering with one of India's premier healthcare institutions, Olympus aims to leverage clinical expertise and insights to drive the development of innovative medical solutions that address the evolving needs of patients worldwide.

Since establishing Olympus Medical Systems India Private Limited in 2009, Olympus has continued to expand its operations in India and has achieved growth with the support of its many stakeholders. These strategic initiatives not only reinforce Olympus’ commitment to advancing medical technology but also strengthen its global footprint and enhance the company’s ability to deliver impactful healthcare solutions.

Comment from Andre Roggan, Chief Technology Officer at Olympus
“It is with great pleasure and excitement that we announce this agreement with HCLTech, with whom we share a decade-long partnership in core engineering and R&D services. I am confident that our collaboration will enhance Olympus’ engineering capabilities and unlock new innovations that enable quality healthcare through technology.”

Comment from Mr. D. Sridhar Babu, Minister of Information Technology, Electronics & Communications (ITE&C) and Industries & Commerce (I&C) of the Government of Telangana
“We are thrilled that Olympus Corporation, one of the world's largest medical device companies, has chosen Hyderabad for its first investment in India with an R&D center, marking a significant milestone for our city's medical devices ecosystem. With Hyderabad's robust infrastructure, strategic location, and thriving community of innovative healthcare companies, this investment is poised to be a game-changer for the medical devices sector in India. We are confident that Olympus' advanced technologies and expertise will significantly contribute to our vision of becoming a global hub for medical device innovation and manufacturing. I welcome Olympus Corporation to our ecosystem.”

About HCLTech

HCLTech is a global technology company, home to more than 227,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud, and AI, powered by a broad portfolio of technology services and products. HCLTech works with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG, and Public Services. Consolidated revenues as of the 12 months ending March 2024 totalled $13.3 billion. To learn how HCLTech can supercharge progress for you, visit hcltech.com.

About Olympus

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit olympus-global.com and follow our global X account:@Olympus_Corp.

Media contact:
Mail: Global-Public_Relations@olympus.com 

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com 



Topic: Press release summary
Source: Olympus

Sectors: Healthcare & Pharm, MedTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Olympus Related News
Tuesday, 19 November 2024, 15:30 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Monday, 30 September 2024, 15:00 JST
Olympus Launches VISERA S, a New Imaging Platform
Friday, 20 September 2024, 15:00 JST
Olympus Launches New 4K Camera Head for Urological Endoscopy
Wednesday, 27 March 2024, 15:00 JST
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
Wednesday, 24 January 2024, 15:00 JST
Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575